Evidence map›Paper›PMID 41209162›Full record

ReviewKidney medicine2025

Qualitative Analysis and Comparison of Externally Led Patient-Focused Drug Development Concepts for Autosomal Recessive Polycystic Kidney Disease Against SONG Initiatives.

Belle Soyfer, Sorin Fedeles, Wendy Ruyle, Elise Hoover, Max C Liebau, Erum A Hartung, Katherine M Dell, Lisa M Guay-Woodford, Ronald D Perrone, Dorothee Oberdhan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Belle SoyferCritical Path Institute, Polycystic Kidney Disease Outcomes Consortium, Tucson, AZ.
Sorin FedelesCritical Path Institute, Polycystic Kidney Disease Outcomes Consortium, Tucson, AZ.
Wendy RuyleCritical Path Institute, Polycystic Kidney Disease Outcomes Consortium, Tucson, AZ.
Elise HooverPKD Foundation, Kansas City, MO.
Max C LiebauDepartment of Pediatrics, Center for Family Health Center for Molecular Medicine Cologne and Center for Rare Disease, University of Cologne, Cologne, Germany.
Erum A HartungDepartment of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, PA.
Katherine M DellCenter for Pediatric Nephrology and Hypertension, Cleveland Clinic Children's Hospital, Cleveland, OH.
Lisa M Guay-WoodfordDepartment of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, PA.
Ronald D PerroneDivision of Nephrology, Tufts Medical Center, Boston, MA.
Dorothee OberdhanOtsuka Pharmaceutical Development & Commercialization, Inc, Rockville, MD.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autosomal recessive polycystic kidney disease (ARPKD) is a rare, inherited condition associated with pathogenic variants in the

Identifiers

PMID41209162
PMCPMC12595366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.